Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates

Company Performance - Nevro reported a quarterly loss of $0.64 per share, better than the Zacks Consensus Estimate of a loss of $0.79, and compared to a loss of $0.15 per share a year ago, indicating an earnings surprise of 18.99% [1] - The company posted revenues of $105.55 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.49%, although this represents a decline from year-ago revenues of $116.18 million [2] - Over the last four quarters, Nevro has exceeded consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - Nevro shares have increased approximately 53.8% since the beginning of the year, contrasting with a decline of -0.5% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.83 on revenues of $94.92 million, and for the current fiscal year, it is -$2.51 on revenues of $405.98 million [7] Industry Outlook - The Medical - Instruments industry, to which Nevro belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Nevro's stock performance [5]